NGS Senior Scientist 1
Tempus AI
Summary
We are seeking a Senior Scientist to lead the development and validation of new molecular assays and laboratory processes for deployment in our clinical laboratory.
Job description
What You'll Do
- Lead development of molecular assays and NGS workflows for high-throughput clinical laboratories.
- Design, execute, and analyze R&D studies with scientific rigor and attention to detail.
- Lead assay validation and clinical implementation from study design through launch, including workflow development, SOP creation, and documentation.
- Design and execute qualification and validation studies for reagents, instruments, equipment, and methods to support clinical deployment.
- Interpret data, troubleshoot issues, and drive process improvements.
- Collaborate across cross-functional teams and provide scientific leadership in a matrixed environment.
- Communicate clearly and effectively with technical and non-technical stakeholders.
- Train and mentor junior scientific staff and support implementation of new laboratory workflows.
- Support automation and technology initiatives to improve laboratory workflows.
- Manage multiple priorities and adapt quickly in a fast-paced environment.
- Travel up to 10% as needed.
Qualifications
- Ph.D. with 0 or more years of experience, or Master's degree with 5+ years of relevant experience in molecular biology, assay development, or a related field.
- Experience in assay development and/or validation required.
- Experience in a clinical laboratory environment required; CAP/CLIA/NYSDOH experience preferred.
- Strong analytical, troubleshooting, and experimental design skills.
- Highly organized, detail-oriented, and committed to quality and accuracy.
- Proven ability to learn quickly and adapt to new processes, technologies, and workflows.
- Strong collaboration skills with the ability to lead across teams.
- Excellent oral and written communication skills.
- Ability to manage competing priorities and deadlines in a dynamic environment.
Preferred Technical Experience
- DNA/RNA extraction and purification methods.
- NGS library preparation, hybrid capture, and sequencing workflows.
- PCR-based techniques, including PCR, qPCR, RT-PCR, and ddPCR.
- Nucleic acid manipulation, quantitation, and analysis.
- Assay troubleshooting, root cause analysis, and workflow optimization.
Highly Desirable
- Experience with liquid biopsy workflows.
- Experience with laboratory automation and liquid handling robotics.
- Experience developing and implementing protocols for CLIA-regulated laboratories.
- Familiarity with LIMS and laboratory data systems.
Requirements
- Ph.D. with 0 or more years of experience, or Master's degree with 5+ years of relevant experience in molecular biology, assay development, or a related field.
- Experience in assay development and/or validation required.
- Experience in a clinical laboratory environment required.
- Strong analytical, troubleshooting, and experimental design skills.
- Highly organized, detail-oriented, and committed to quality and accuracy.
- Proven ability to learn quickly and adapt to new processes, technologies, and workflows.
- Strong collaboration skills with the ability to lead across teams.
- Excellent oral and written communication skills.
- Ability to manage competing priorities and deadlines in a dynamic environment.
Benefits
- Incentive compensation
- Restricted stock units
- Medical benefits
Company overview
Tempus AI, Inc. (NASDAQ: TEM) is a pioneering healthcare technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company was established after Lefkofsky's wife was diagnosed with breast cancer, driving his mission to revolutionize cancer care through technology and artificial intelligence. Tempus specializes in applying AI to advance precision medicine by collecting and analyzing vast amounts of molecular, clinical, and genomic data. The company operates across multiple therapeutic areas including oncology, cardiology, radiology, neurology, psychiatry, and dermatology. Tempus provides comprehensive diagnostic services including next-generation sequencing (NGS), PCR profiling, and molecular pathology testing. Its AI-powered platform enables physicians to make real-time, data-driven decisions for personalized patient care and targeted therapies. The company went public in June 2024 and has expanded globally with operations in multiple countries. Tempus continues to innovate at the intersection of healthcare and artificial intelligence, aiming to ensure patients receive the right treatments at the right time for improved health outcomes.